Pfizer (PFE) Free Cash Flow (2009 - 2026)

Pfizer (PFE) has reported Free Cash Flow for 18 consecutive years, with $302.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Free Cash Flow rose 125.17% year-over-year to $302.0 million in Q2 2026; TTM through Jun 2026 was $11.0 billion, a 402.98% increase from a year earlier, with the FY2025 full-year figure at $9.1 billion, down 7.73% from the prior year.
• Free Cash Flow was $302.0 million for Q2 2026 at Pfizer, down from $2.2 billion in the prior quarter.
• Over five years, Free Cash Flow peaked at $7.4 billion in Q3 2022 and troughed at -$2.4 billion in Q2 2024.
• A 5-year average of $2.1 billion and a median of $2.0 billion in 2025 frame the typical range for Free Cash Flow.
• Across the five-year window, Free Cash Flow sank 128.58% in 2023 and jumped 428.77% in 2024, its largest moves.
• Over 5 years, Free Cash Flow stood at $7.4 billion in 2022, then slumped by 43.49% to $4.2 billion in 2023, then slipped by 3.93% to $4.0 billion in 2024, then advanced by 11.71% to $4.5 billion in 2025, then sank by 93.29% to $302.0 million in 2026.
• The last three Free Cash Flow figures came in at $302.0 million (Q2 2026), $2.2 billion (Q1 2026), and $4.5 billion (Q4 2025), per Business Quant data.